BioMarin (BMRN) Q3 2026 Earnings
Non-GAAP EPS includes acquired IPR&D charges of $287.7 million (287,685 thousand) recorded in the quarter in connection with the Alesta Therapeutics acquisition; company expects Alesta and BMN 450 charges of approximately $320 million and $83 million for full-year 2026 (approximately $1.55 and $0.32 per share). GAAP diluted EPS of $(0.63) also reflects Amicus-related intangible amortization ($99 million), inventory step-up amortization ($18 million) and acquisition/restructuring costs ($47 million).
How Did BMRN Stock React to Q3 2026 Earnings?
Did BMRN Beat Earnings? Q3 2026 Results
Yes. BioMarin reported Q3 2026 earnings of $0.23 a share on Nov 2, 2026, beating the $-0.11 consensus estimate by 304.8%. Revenue was $1.0B against a $1.0B estimate.
BioMarin Pharmaceutical delivered a decisive earnings beat in Q3 2026, its first full quarter absorbing the Amicus Therapeutics product portfolio, as adjusted non-GAAP EPS of $0.23 cleared the consensus estimate of negative $0.11 by 304.81% while revenue of $1.02 billion edged ahead of expectations and climbed 32.0% year over year. The Amicus integration was the clear engine of that growth, with GALAFOLD contributing $152.00 million and POMBILITI + OPFOLDA adding $49.00 million as patient counts rose sharply across both therapies. The GAAP picture was far cloudier: a $287.69 million acquired in-process R&D charge tied to the Alesta Therapeutics acquisition, alongside $99.46 million of intangible amortization and $55.63 million of interest expense on acquisition debt, pushed the GAAP net loss to $123.00 million. Looking ahead, BioMarin trimmed its full-year 2026 revenue outlook to $3.80 billion to $3.90 billion, partly on uncertain order timing from a single international customer, and lowered its non-GAAP diluted EPS guidance to $2.80 to $3.10, reflecting roughly $403.00 million in combined Alesta and BMN 450 pre-tax charges.
- Addition of GALAFOLD ($152M) and POMBILITI + OPFOLDA ($49M) from the Amicus acquisition
- Patients treated with GALAFOLD and POMBILITI + OPFOLDA up about 13% and 69% Y/Y
- POMBILITI + OPFOLDA uptake helped by supply constraints for other Pompe therapies
- VIMIZIM revenue up 18% on timing of large international orders
- VOXZOGO up 12%, with children treated up 17% Y/Y across 58 countries
- NAGLAZYME down 11% on timing of large international orders
- GAAP loss widened on Amicus intangible amortization, interest expense, inventory step-up and integration costs, plus the Alesta IPR&D charge
- Higher sales and marketing spend for GALAFOLD and POMBILITI + OPFOLDA
“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin.”
BioMarin CEO, on the earnings call
What Is BioMarin's Outlook?
BioMarin updated its full-year 2026 guidance to reflect order-timing uncertainty and two acquired IPR&D charges. - Total revenues: $3,800–$3,900 million, from $3,875–$3,925 million; implies 20% midpoint growth. - Metabolic Conditions: $2,675–$2,750 million; 29% midpoint growth. - VOXZOGO: $975–$1,025 million; 8% midpoint growth. - Other revenues: $125–$150 million, from $100–$125 million. - Non-GAAP diluted EPS: $2.80–$3.10, from $4.90–$5.10; based on about 200 million diluted shares. The EPS cut reflects about $320 million (Alesta) and $83 million (BMN 450) of pre-tax charges, or roughly $1.55 and $0.32 per share. A large international VOXZOGO order has moved from Q3 to Q4. Upcoming milestones: - VOXZOGO achondroplasia full-approval PDUFA date: February 28, 2027. - VOXZOGO hypochondroplasia PDUFA date: May 30, 2027. - BMN 333 and BMN 440 data: 2027. - BMN 820 pivotal data: 2028. - Amicus cost synergies of about $280 million GAAP (about $220 million non-GAAP) fully realized in 2028.
BMRN YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.0B | $776.1M | +32.0% |
| Operating Income | −$82.1M | −$339.0M | −75.8% |
BMRN Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.